The Strength Is Deceptive
The indices look strong this morning and breadth is nearly 4-to-1 positive, but under the surface I'm not seeing the sort of frenzied buying those facts might suggest. In fact, I'm seeing quite a few fades, and key names like Apple (AAPL) don't seem to be gaining any traction.
Small biotechnology names continue to attract attention with stocks like Affymax (AFFY), Orexigen Therapeutics (OREX) and Medgenics (MDGN) running. Merck (MRK) is leading big-cap names, and homebuilders are probably the hottest group....105 more words left in this article. To read them, just click below and try Real Money FREE for 14 days.
There’s no substitute for a trading floor to get great ideas, so Jim Cramer created a better one at Real Money and blogs there exclusively. We then added legendary hedge fund manager, Doug Kass, with his exclusive Daily Diary and best investing ideas. Staffed with more than 4 dozen investing pros, money managers, journalists and analysts, Real Money Pro gives you a flood of opinions, analysis and actionable trading advice found nowhere else, and allows you to interact directly with each expert.
Already a Subscriber? Please login.